Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer
A Phase I, First-In-Human, Multicenter, Open-Label Study of TT-00420, Administered Orally in Adult Patients With Advanced Solid Tumors and Triple Negative Breast Cancers
Sponsor: TransThera Sciences (Nanjing), Inc.
A PHASE1 clinical study on Advanced Solid Tumors and Triple Negative Breast Cancer, this trial is completed. The trial is conducted by TransThera Sciences (Nanjing), Inc. and has accumulated 13 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Aug 2025 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2024 — Aug 2025 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Feb 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
Status: Unknown Status → Active Not Recruiting
-
Sep 2023 — Feb 2024 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
▶ Show 8 earlier versions
-
Nov 2021 — Sep 2023 [monthly]
Active Not Recruiting PHASE1
-
Sep 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Aug 2019 — Sep 2020 [monthly]
Recruiting PHASE1
-
May 2019 — Aug 2019 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Oct 2018 — May 2019 [monthly]
Not Yet Recruiting PHASE1
-
Sep 2018 — Oct 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- TransThera Sciences (Nanjing), Inc.
For direct contact, visit the study record on ClinicalTrials.gov .